Table 3 Baseline characteristics of the patients grouped according to the presence of Nabs
Characteristics | NAbs status | P | |
|---|---|---|---|
| Â | Negative (n = 124) | Positive (n = 17) | Â |
Gender | Â | Â | Â |
   Female | 80 [64.5] | 10 [58.8] | 0.65 |
   Male | 44 [35.5] | 7 [41.2] | 0.65 |
Age (years) | 38 ± 9.4 (21-64) | 43 ± 10.8 (31-67) | 0.046 |
Disease duration (years) | 11 ± 5.8 (2-29) | 11 ± 7.4 (3-34) | 0.92 |
Treatment duration (in years) | 4 ± 2.2 (1-10) | 4 ± 1.7 (1-7) | 0.14 |
IFNβ type |  |  | 0.96 |
   Avonex (n = 12) | 11 [8.9] | 1 [5.9] |  |
   Betaferon (n = 36) | 31 [25.0] | 5 [29.4] |  |
   Rebif 22 (n = 48) | 42 [33.8] | 6 [35.3] |  |
   Rebif 44 (n = 45) | 40 [32.3] | 5 [29.4] |  |